TheraVet Optimizes Its Commercial Strategy in France With a New Distribution Agreement for Its BIOCERA-VET® Range
12 Dezember 2022 - 07:30AM
Business Wire
- TheraVet announces the signing of a new agreement for
BIOCERA-VET® with Elvetis, specialist in the distribution of animal
health products
- This agreement allows TheraVet to refocus its efforts on its
network of high-potential clinics by relying on a specialized
distributor with its own sales force in France
Regulatory News:
TheraVet (ISIN code: BE0974387194 - mnemonic: ALVET), a
pioneering biotechnology company in the treatment of bone and joint
diseases in pets, today announces the signing of a new exclusive
distribution agreement for its line of bone substitutes
BIOCERA-VET® with Elvetis, one of the main specialists in animal
health products in France. The whole range, namely BIOCERA-VET®
Bone Surgery (BS) RTU, BIOCERA-VET® BS Granules, BIOCERA-VET® BS
SmartGraft and BIOCERA-VET® Osteosarcoma, is covered by this
agreement.
Elvetis is one of the French subsidiaries of the Neftys Pharma
group, a distributor of veterinary products for 30 years, the
French company puts its expertise every day at the service of more
than 7,500 customers in France and several European countries,
thanks to a diversified product portfolio and the know-how of its
employees. Neftys Pharma is specializing in veterinary distribution
which generates more than €450 million in turnover. The family
business has asserted its international presence for several years,
allowing it today to be among the leaders in veterinary
distribution in Europe.
Through this agreement, TheraVet strengthens and optimizes its
distribution strategy in France, which includes a direct approach
for its network of very high-potential clinics and an indirect
approach for the rest of the veterinary clinics based on a partner
with a sales force in the field targeting its population of
prescribers. TheraVet now has better leverage to market the
BIOCERA-VET® line in the second largest companion animal market in
Europe with a population of 22 million dogs and cats1.
Enrico Bastianelli, Managing Director of TheraVet,
comments: "This new agreement concluded with a quality partner
of Elvetis will allow BIOCERA-VET® to benefit from a double
leverage effect - direct and indirect - on the French market. It is
a fine example of optimizing TheraVet's commercial strategy: focus
our own commercial forces on very high-potential prescribers and
rely on solid distributors to maximize the penetration of our
products. »
Nicolas LANG, Managing Director of NEFTYS PHARMA: “I am
enthusiastic about the idea of starting this ambitious
collaboration with TheraVet and contributing to the French
development of their innovative BIOCERA-VET® range. Theravet
products represent a major advance in the surgical treatment of
osteoarticular lesions in companion animals. Validated by
specialist veterinarians, they offer a high level of quality in
terms of both efficacy and safety. They are also easy to use. »
About TheraVet
TheraVet is a veterinary biotechnology company specializing in
bone and joint treatments in animal health. The Company develops
targeted, safe and effective treatments to improve the quality of
life of companion animals suffering from joint and bone diseases.
The health of pets is at the heart of their owners' concerns and
TheraVet's mission is to meet the need for innovative and curative
treatments. TheraVet works closely with international thought
leaders to better meet the ever-growing needs of veterinary
medicine. TheraVet is listed on Euronext Growth® Paris and
Brussels, its head office is located in Gosselies, Belgium, and the
Company has a US subsidiary.
For more information, visit our website or follow us on LinkedIn
/ Facebook / Twitter.
About BIOCERA-VET®
BIOCERA-VET® is a complete range of innovative, easy-to-use,
effective and cost-effective bone substitutes indicated in bone
surgeries requiring bone grafting as well as in the palliative
management of canine osteosarcoma. Based on extremely promising
clinical results, this product line allows an evolution towards
simpler and more efficient orthopedic surgery.
BIOCERA-VET® is available in several lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use cement based on
highly injectable and self-hardening calcium phosphate
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, a bone substitute based on biocompatible
and affordable calcium phosphate
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use bone substitute
based on highly injectable calcium phosphate for cementoplasty
For more information, visit our site BIOCERA-VET.
1 Annual Report 2020 FEDIAF (Fédération Européenne de
l’Industrie des Aliments pour Animaux Familiers)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221211005018/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tél. : +32 (0) 71 96 00 43 Chief Corporate
Officer Julie Winand investors@thera.vet
NewCap Relations Investisseurs & Communication
Financière Théo Martin / Nicolas Fossiez theravet@newcap.eu Tél. :
+33 (0) 1 44 71 94 94 Relations Presse Arthur Rouillé
theravet@newcap.eu Tél. : +33 (0) 1 44 71 00 15
NewCap Belgique Relations Presse Laure-Eve Monfort
lemonfort@newcap.fr Tél. : + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
Von Feb 2023 bis Mär 2023
TheraVet (EU:ALVET)
Historical Stock Chart
Von Mär 2022 bis Mär 2023
